2024-03-25 14:29:08 ET
Summary
- Iovance's tumor-infiltrating lymphocyte (TIL) product, Amtagvi, was recently approved by the FDA for the treatment of advanced melanoma patients who have failed a PD-1 blocking antibody.
- Initial numbers from the early days of the launch can be considered when trying to project revenues from Amtagvi going forward.
- IOVA can improve potential revenues by gaining approval of its TIL therapies like Amtagvi outside of the US and in new indications.
- In the short term, however, the focus may be on the current Amtagvi launch, where some success may already be reflected in the price.
Read the full article on Seeking Alpha
For further details see:
Iovance Biotherapeutics: Initial Amtagvi Launch In Focus